These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8070011)

  • 1. Renal function in children and adolescents following 72 g/m2 of ifosfamide.
    Arndt C; Morgenstern B; Wilson D; Liedtke R; Miser J
    Cancer Chemother Pharmacol; 1994; 34(5):431-3. PubMed ID: 8070011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma.
    Arndt C; Morgenstern B; Hawkins D; Wilson D; Liedtke R; Miser J
    Med Pediatr Oncol; 1999 Feb; 32(2):93-6. PubMed ID: 9950195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.
    Suarez A; McDowell H; Niaudet P; Comoy E; Flamant F
    J Clin Oncol; 1991 Dec; 9(12):2177-82. PubMed ID: 1720453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
    Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
    Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
    Antman KH; Elias A; Ryan L
    Semin Oncol; 1990 Apr; 17(2 Suppl 4):68-73. PubMed ID: 2110386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal dysfunctions secondary to ifosfamide treatment in children.
    Tokuc G; Yalçiner A; Kebudi R; Dogan S; Görgün O; Ayan I
    J Exp Clin Cancer Res; 1997 Jun; 16(2):227-30. PubMed ID: 9261752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group.
    Skinner R; Cotterill SJ; Stevens MC
    Br J Cancer; 2000 May; 82(10):1636-45. PubMed ID: 10817497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of age on nephrotoxicity following chemotherapy in children.
    Skinner R; Pearson AD; Price L; Coulthard MG; Craft AW
    Br J Cancer Suppl; 1992 Aug; 18():S30-5. PubMed ID: 1503924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ifosfamide-induced subclinical nephrotoxicity and its potentiation by cisplatinum.
    Rossi R; Danzebrink S; Hillebrand D; Linnenbürger K; Ullrich K; Jürgens H
    Med Pediatr Oncol; 1994; 22(1):27-32. PubMed ID: 8232077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephrotoxicity after ifosfamide.
    Skinner R; Pearson AD; Price L; Coulthard MG; Craft AW
    Arch Dis Child; 1990 Jul; 65(7):732-8. PubMed ID: 2386379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tubular nephrotoxicity during long-term ifosfamide and mesna therapy.
    Goren MP; Pratt CB; Viar MJ
    Cancer Chemother Pharmacol; 1989; 25(1):70-2. PubMed ID: 2574077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal function in long-term survivors of stem cell transplantation in childhood. A prospective trial.
    Patzer L; Ringelmann F; Kentouche K; Fuchs D; Zintl F; Brandis M; Zimmerhackl LB; Misselwitz J
    Bone Marrow Transplant; 2001 Feb; 27(3):319-27. PubMed ID: 11277181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal function abnormalities after ifosfamide treatment in children.
    De Schepper J; Hachimi-Idrissi S; Verboven M; Piepsz A; Otten J
    Acta Paediatr; 1993 Apr; 82(4):373-6. PubMed ID: 8318805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose.
    Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
    Pediatr Blood Cancer; 2010 Jul; 54(7):983-9. PubMed ID: 20405516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma.
    Koch Nogueira PC; Hadj-Aïssa A; Schell M; Dubourg L; Brunat-Mentigny M; Cochat P
    Pediatr Nephrol; 1998 Sep; 12(7):572-5. PubMed ID: 9761357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors.
    Hartmann JT; Fels LM; Knop S; Stolt H; Kanz L; Bokemeyer C
    Invest New Drugs; 2000 Aug; 18(3):281-9. PubMed ID: 10958599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for ifosfamide nephrotoxicity in children.
    Skinner R; Pearson AD; English MW; Price L; Wyllie RA; Coulthard MG; Craft AW
    Lancet; 1996 Aug; 348(9027):578-80. PubMed ID: 8774570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ifosfamide-induced nephrotoxicity].
    Rossi R; Rath B; Ullrich K; Ehrich JH
    Monatsschr Kinderheilkd; 1993 Jul; 141(7):594-601. PubMed ID: 8413339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity of high-dose ifosfamide in children.
    Davies SM; Pearson AD; Craft AW
    Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S8-10. PubMed ID: 2503259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma.
    Stuart-Harris RC; Harper PG; Parsons CA; Kaye SB; Mooney CA; Gowing NF; Wiltshaw E
    Cancer Chemother Pharmacol; 1983; 11(2):69-72. PubMed ID: 6414732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.